NASHVILLE, TENN., April 15, 2016 – Sarah Cannon Research Institute announced today that the American Association for Cancer Research (AACR) has selected 16 abstracts authored by Sarah Cannon investigators to be presented at the 2016 AACR Annual Meeting, held April 16 – 20 in New Orleans, La. The annual meeting brings together researchers and cancer professionals from across the world to discuss the latest developments in clinical research. The theme of this year’s meeting, "Delivering Cures Through Cancer Science," reinforces the crucial role of clinical trials in advancing patient care.
Sarah Cannon research leaders will highlight initial findings from ongoing phase I studies for immunotherapies and molecular targeted agents in mini-symposiums and plenary sessions at the meeting.
“We look forward to sharing valuable insights from studies across our network that focus on the investigation of novel therapies,” said Howard A. “Skip” Burris III, MD, Chief Medical Officer at Sarah Cannon. “As we continue to better understand genetic drivers of cancer and ways to harness the body’s own immune system to fight the disease, we are getting more targeted in our approach to advancing therapies for patients.”
Sarah Cannon investigators presenting noteworthy studies at the annual meeting include:
- Jeffrey Infante, MD, director of drug development at Sarah Cannon Research Institute, has an oral presentation in a plenary session on anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors. Dr. Infante will also present a poster on a phase I trial for GSK3174998 administered alone and in combination with pembrolizumab.
- Todd Bauer, MD, associate director of drug development at Sarah Cannon Research Institute will highlight initial findings of a phase Ib clinical trial investigating AZD1775 in the “Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome” mini-symposium.
- Charles Swanton, Sarah Cannon UK's personalized medicine lead and professor of personalized medicine at UCL Cancer Institute, will chair a workshop and plenary session on tumor heterogeneity, among other presentations.
In addition, the following Sarah Cannon investigators have abstracts selected for oral presentations and poster sessions: Hendrik-Tobias Arkenau, MD, PhD, FRCP, Todd M. Bauer, MD, Johanna C. Bendell, MD, Howard A. “Skip” Burris, MD, Gerald Falchook, MD, Carol Greenlees, PhD, Lowell L. Hart, MD, Melissa Johnson, MD, Suzanne F. Jones, PharmD, Kathleen Moore, MD, Manish Patel, MD, Kent C. Shih, MD, David Spigel, MD, Judy Wang, MD, and Denise A. Yardley, MD.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US. Please click here to earn more about our research offerings.
Media Contact:
Samantha Maxwell